Maternal and obstetric outcomes after Ex-Utero Intrapartum Treatment (EXIT): a single center experience.


Journal

BMC pregnancy and childbirth
ISSN: 1471-2393
Titre abrégé: BMC Pregnancy Childbirth
Pays: England
ID NLM: 100967799

Informations de publication

Date de publication:
02 Dec 2023
Historique:
received: 27 09 2023
accepted: 14 11 2023
medline: 4 12 2023
pubmed: 3 12 2023
entrez: 2 12 2023
Statut: epublish

Résumé

The Ex-utero Intrapartum Treatment (EXIT) is a procedure developed to manage a range of fetal conditions, aiming to ensure the maintenance of neonatal airway and preserving the feto-placental circulation. Its goal is to enhance the neonatal ability to successfully transition and adapt to postnatal life, thereby reducing perinatal morbidity and mortality. However, EXIT has been associated with a high risk of maternal complications. This paper provides an overview of the indications and characteristics of the EXIT procedure, as well as the obstetric outcomes and maternal complications. A retrospective analysis was conducted on a cohort of patients undergoing EXIT at our center between January 2007 and December 2022. Maternal outcomes, including demographic information, data related to the surgical procedure, surgical complications, and postoperative complications were analyzed. To assess the severity of the surgical complications, a modified Clavien-Dindo classification was used. Comparative analysis was performed by randomly selecting a sample from elective cesarean deliveries performed at our center. A total of 34 EXIT procedures were performed. According to the modified Clavien-Dindo classification, we observed no major complications, while minor maternal complications were present in 2.94% of cases. Compared to elective cesarean deliveries (n = 350), there were no significant differences in terms of maternal complications, highlighting the similarity observed in the mean decrease in postoperative hemoglobin (1.15 g/dL in EXIT vs. 1.2 g/dL in elective cesarean deliveries, p = 0.94). In EXIT group, there was a higher rate of polyhydramnios (26.47% vs 6.59%, p < 0.001), as well as the need for amnioreduction (14.71% vs 0%, p = 0.001) and preterm delivery (32.35% vs 6.02%, p = 0.001). There were no cases of endometritis, post-procedural fever, or abruptio placentae following EXIT. EXIT can be considered a safe procedure when performed under adequate conditions, including appropriate uterine access and proper anesthetic management. In our series, EXIT procedure was not associated with a higher incidence of maternal complications when compared to elective cesarean delivery. Retrospectively registered.

Sections du résumé

BACKGROUND BACKGROUND
The Ex-utero Intrapartum Treatment (EXIT) is a procedure developed to manage a range of fetal conditions, aiming to ensure the maintenance of neonatal airway and preserving the feto-placental circulation. Its goal is to enhance the neonatal ability to successfully transition and adapt to postnatal life, thereby reducing perinatal morbidity and mortality. However, EXIT has been associated with a high risk of maternal complications. This paper provides an overview of the indications and characteristics of the EXIT procedure, as well as the obstetric outcomes and maternal complications.
METHODS METHODS
A retrospective analysis was conducted on a cohort of patients undergoing EXIT at our center between January 2007 and December 2022. Maternal outcomes, including demographic information, data related to the surgical procedure, surgical complications, and postoperative complications were analyzed. To assess the severity of the surgical complications, a modified Clavien-Dindo classification was used. Comparative analysis was performed by randomly selecting a sample from elective cesarean deliveries performed at our center.
RESULTS RESULTS
A total of 34 EXIT procedures were performed. According to the modified Clavien-Dindo classification, we observed no major complications, while minor maternal complications were present in 2.94% of cases. Compared to elective cesarean deliveries (n = 350), there were no significant differences in terms of maternal complications, highlighting the similarity observed in the mean decrease in postoperative hemoglobin (1.15 g/dL in EXIT vs. 1.2 g/dL in elective cesarean deliveries, p = 0.94). In EXIT group, there was a higher rate of polyhydramnios (26.47% vs 6.59%, p < 0.001), as well as the need for amnioreduction (14.71% vs 0%, p = 0.001) and preterm delivery (32.35% vs 6.02%, p = 0.001). There were no cases of endometritis, post-procedural fever, or abruptio placentae following EXIT.
CONCLUSIONS CONCLUSIONS
EXIT can be considered a safe procedure when performed under adequate conditions, including appropriate uterine access and proper anesthetic management. In our series, EXIT procedure was not associated with a higher incidence of maternal complications when compared to elective cesarean delivery.
TRIAL REGISTRATION BACKGROUND
Retrospectively registered.

Identifiants

pubmed: 38042795
doi: 10.1186/s12884-023-06129-9
pii: 10.1186/s12884-023-06129-9
pmc: PMC10693058
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

831

Informations de copyright

© 2023. The Author(s).

Références

Children (Basel). 2022 Mar 15;9(3):
pubmed: 35327788
J Anesth. 2019 Dec;33(6):665-669
pubmed: 31598782
BMC Pregnancy Childbirth. 2020 Oct 7;20(1):598
pubmed: 33028259
Am J Obstet Gynecol. 2002 Apr;186(4):773-7
pubmed: 11967506
J Laryngol Otol. 2020 Jul;134(7):650-653
pubmed: 32605677
Semin Pediatr Surg. 2021 Jun;30(3):151066
pubmed: 34172204
Eur J Pediatr Surg. 2023 Sep 08;:
pubmed: 37473779
Einstein (Sao Paulo). 2017 Oct-Dec;15(4):10-11
pubmed: 29364359
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
World J Pediatr Surg. 2022 Jul 27;5(4):e000425
pubmed: 36474729
Prenat Diagn. 2022 Oct;42(11):1420-1428
pubmed: 36045557
Prenat Diagn. 2019 Mar;39(4):251-268
pubmed: 30703262
J Pediatr Surg. 2017 Jan;52(1):22-25
pubmed: 27836357
J Obstet Gynaecol. 2010 Jan;30(1):1-5
pubmed: 20121493
J Gynecol Obstet Hum Reprod. 2022 Jan;51(1):102252
pubmed: 34638008
Anaesthesia. 2021 Apr;76 Suppl 4:63-68
pubmed: 33682103
J Pediatr Surg. 2013 May;48(5):951-5
pubmed: 23701766
Semin Pediatr Surg. 2019 Aug;28(4):150820
pubmed: 31451172
Einstein (Sao Paulo). 2017 Oct-Dec;15(4):395-402
pubmed: 29364360
J Pediatr Surg. 2020 Jul;55(7):1188-1195
pubmed: 32151401
J Paediatr Child Health. 2013 Sep;49(9):E420-7
pubmed: 23662685
Int J Pediatr Otorhinolaryngol. 2022 Jan;152:110982
pubmed: 34794813
Semin Pediatr Surg. 2006 May;15(2):107-15
pubmed: 16616314

Auteurs

Marta Domínguez-Moreno (M)

Department of Materno-Fetal Medicine, Genetics and Reproduction, Institute of Biomedicine of Seville (IBIS), Hospital Universitario Virgen del Rocio/CSIC/University of Seville, Seville, Spain.

Ángel Chimenea (Á)

Department of Materno-Fetal Medicine, Genetics and Reproduction, Institute of Biomedicine of Seville (IBIS), Hospital Universitario Virgen del Rocio/CSIC/University of Seville, Seville, Spain.
Fetal, IVF and Reproduction Simulation Training Centre (FIRST), Seville, Spain.

Lutgardo García-Díaz (L)

Department of Materno-Fetal Medicine, Genetics and Reproduction, Institute of Biomedicine of Seville (IBIS), Hospital Universitario Virgen del Rocio/CSIC/University of Seville, Seville, Spain. lgarcia14@us.es.
Department of Surgery, University of Seville, Seville, Spain. lgarcia14@us.es.

Guillermo Antiñolo (G)

Department of Materno-Fetal Medicine, Genetics and Reproduction, Institute of Biomedicine of Seville (IBIS), Hospital Universitario Virgen del Rocio/CSIC/University of Seville, Seville, Spain. gantinolo@us.es.
Fetal, IVF and Reproduction Simulation Training Centre (FIRST), Seville, Spain. gantinolo@us.es.
Department of Surgery, University of Seville, Seville, Spain. gantinolo@us.es.
Centre for Biomedical Network Research On Rare Diseases (CIBERER), Seville, Spain. gantinolo@us.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH